Pharma BD Deal Intelligence
Merck paid $11.5B for Acceleron to acquire sotatercept, a first-in-class activin signaling inhibitor for pulmonary arterial hypertension. Marketed as Winrevair (approved 2024; label expanded Oct 2025 on the ZENITH trial to include reduced risk of clinical worsening and death), it reached $525M in Q1 2026 sales (+88% YoY) on a >$2B annualized run-rate — a blockbuster in a disease with no prior disease-modifying therapy.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck.
FDA approved updated WINREVAIR indication (Oct 27, 2025) adding reduced risk of clinical worsening (hospitalization for PAH, lung transplantation, death);…
WINREVAIR Q1 2026 sales $525M (88% growth; 87% ex-FX), driven by continued U.S. uptake and early launch in Japan and Europe.
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Merck acquired Acceleron Pharma for approximately $11.5 billion ($180 per share in cash), gaining sotatercept, an investigational first-in-class activin signaling inhibitor in Phase III for pulmonary arterial hypertension, and REBLOZYL (luspatercept) for anemia in rare blood disorders.
50K US cases/yr · $7.5B Global PAH Market (2024)
Pulmonary arterial hypertension is a progressive, life-threatening disease of the pulmonary vasculature. WINREVAIR (sotatercept) is the first disease-modifying therapy, acting on the TGF-beta superfamily to rebalance vascular cell proliferation. STELLAR showed unprecedented 84% reduction in death or clinical worsening.
WINREVAIR approved March 2024 as first-in-class activin signaling inhibitor. Q2 2024 sales of $70M exceeded expectations. Analysts project $2B+ peak sales by 2028. Background therapies (ERA, PDE5i, prostacyclin) remain standard but WINREVAIR adds on top as disease-modifying agent.
Merck & Co. Inc. completed its acquisition of Acceleron Pharma Inc. for $11.5B. Transaction marks a key portfolio move in Acquisition/Merger strategy.
Sotatercept met primary endpoint, hitting 8/9 secondary endpoints in PAH. Part of Merck & Co. Inc.'s $11.5B deal to acquire Acceleron Pharma Inc..
FDA approved Winrevair on Mar 26, 2024 for pulmonary arterial hypertension — first activin-signaling inhibitor for PAH. Validates Merck's $11.5B Acceleron acquisition thesis.
Q3 2025 sales of $360M. Analysts project $7.2B peak by 2035. Reflects financial performance following Merck & Co. Inc.'s $11.5B acquisition of Acceleron Pharma Inc..
FDA approved an updated WINREVAIR (sotatercept-csrk) indication based on the Phase 3 ZENITH trial, adding reduced risk of clinical worsening events (hospitalization for PAH, lung transplantation, death). ZENITH showed a 76% reduction in major morbidity/mortality (HR 0.24, p<0.0001) and was stopped early for overwhelming efficacy.
Merck reported Q1 2026 WINREVAIR sales of $525 million, up 88% year-over-year (87% ex-FX), ahead of consensus (~$487M), driven by continued U.S. uptake and early launches in Japan and Europe. Puts Winrevair on a >$2B annualized run-rate, confirming blockbuster status.
First disease-modifying PAH treatment. $360M/quarter with $7.2B peak. $11.5B looks like a bargain.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Acceleron Pharma Inc. (this deal) | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
| Merck & Co. Inc. / Prometheus Biosciences Inc. | 2023 | $10.8B | 77 |
← Browse all deals · How we score deals
More: 2021 deals · Merck & Co. Inc. deals · Cardiovascular deals